GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eliem Therapeutics Inc (NAS:ELYM) » Definitions » Asset Turnover

Eliem Therapeutics (Eliem Therapeutics) Asset Turnover : 0.00 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Eliem Therapeutics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Eliem Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Eliem Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was $109.90 Mil. Therefore, Eliem Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Eliem Therapeutics's annualized ROE % for the quarter that ended in Mar. 2024 was -6.34%. It is also linked to ROA % through Du Pont Formula. Eliem Therapeutics's annualized ROA % for the quarter that ended in Mar. 2024 was -6.18%.


Eliem Therapeutics Asset Turnover Historical Data

The historical data trend for Eliem Therapeutics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eliem Therapeutics Asset Turnover Chart

Eliem Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
- - - - -

Eliem Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Eliem Therapeutics's Asset Turnover

For the Biotechnology subindustry, Eliem Therapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eliem Therapeutics's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eliem Therapeutics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Eliem Therapeutics's Asset Turnover falls into.



Eliem Therapeutics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Eliem Therapeutics's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (134.992+110.469)/ 2 )
=0/122.7305
=0.00

Eliem Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0/( (110.469+109.334)/ 2 )
=0/109.9015
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Eliem Therapeutics  (NAS:ELYM) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Eliem Therapeutics's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-6.788/106.9915
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-6.788 / 0)*(0 / 109.9015)*(109.9015/ 106.9915)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.0272
=ROA %*Equity Multiplier
=-6.18 %*1.0272
=-6.34 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Eliem Therapeutics's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-6.788/109.9015
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-6.788 / 0)*(0 / 109.9015)
=Net Margin %*Asset Turnover
= %*0
=-6.18 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Eliem Therapeutics Asset Turnover Related Terms

Thank you for viewing the detailed overview of Eliem Therapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Eliem Therapeutics (Eliem Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
23515 NE Novelty Hill Road, Suite B221 No. 125, Redmond, WA, USA, 98053
Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems.
Executives
Emily Pimblett officer: Chief Accounting Officer C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
Ai Eti Llc 10 percent owner C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Judith Dunn director C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Valerie Morisset officer: Chief Scientific Officer C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
Andrew David Levin director C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
Simon Tate director C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
Adam Joseph Rosenberg director C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053
James B Bucher officer: EVP and General Counsel 11804 NORTH CREEK PARKWAY S, BOTHELL WA 98011
Ra Capital Nexus Fund Ii, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Erin Lavelle officer: COO & CFO C/O ALDER BIOPHARMACEUTICALS, INC., 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Ra Capital Nexus Fund, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Len Blavatnik other: Affiliate of 10% Owner C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019
Liam Ratcliffe director C/O ACCESS INDUSTRIES, INC, 40 WEST 57TH ST, 28TH FLOOR, NEW YORK NY 10019
Robert Azelby director, officer: Chief Executive Officer 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109